BiotechTube

Loncastuximab Tesirine + Rituximab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed or Refractory Large B-cell Lymphoma

Conditions

Relapsed or Refractory Large B-cell Lymphoma

Trial Timeline

Aug 25, 2025 → Mar 1, 2030

NCT ID
NCT06788964

About Loncastuximab Tesirine + Rituximab

Loncastuximab Tesirine + Rituximab is a phase 2 stage product being developed by ADC Therapeutics for Relapsed or Refractory Large B-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06788964. Target conditions include Relapsed or Refractory Large B-cell Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT06788964Phase 2Recruiting
NCT05144009Phase 2Terminated
NCT04998669Phase 2Recruiting

Competing Products

20 competing products in Relapsed or Refractory Large B-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
agenT-797MiNK TherapeuticsPhase 1
25
VIP152 + BTKiVincerx PharmaPhase 1
25
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
77
AC220Daiichi SankyoPhase 1
33
Valemetostat TosylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
AGS67EAstellas PharmaPhase 1
33
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
41
LenvatinibEisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
Eribulin mesylateEisaiPhase 2
52
ME-401Kyowa KirinPhase 1
33
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6Kyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
ONO-4685Ono PharmaceuticalPhase 1
33
ONO-4685Ono PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77

Other Products from ADC Therapeutics

Loncastuximab Tesirine + Rituximab + Gemcitabine + OxaliplatinPhase 3
69
Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/KgPhase 2
44
Loncastuximab tesirine + RituximabPhase 2
44
Loncastuximab tesirinePhase 2
44
Loncastuximab Tesirine + RituximabPhase 2
44